A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

Brief description of study

This is a research study to evaluate the safety and effectiveness of the study drug donanemab to see if it will help slow the mental and functional changes of Alzheimer’s disease. To participate in this study, you must have a reliable study partner with whom you live or have regular contact (who communicates with you at least 10 hours each week), and who can come with you to study visits or can be called during study visits.

Clinical Study Identifier: s21-00113
ClinicalTrials.gov Identifier: NCT04437511
Principal Investigator: Martin Sadowski.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.